The effect of canagliflozin on body fat volume

The effect of canagliflozin on body fat volume - Canagliflozin for body fat

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021327

Enrollment

Registered

2016-03-31

Start date

2016-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Administration of 100 mg of canagliflozin for 6 month

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes

Exclusion criteria

Exclusion criteria: Hypersensitivity to canagliflozin, Complicated with sever ketoacidosis, diabetic coma, Type 1 diabetes Complicated with severe infection, sever trauma

Design outcomes

Primary

Measure	Time frame
Epicardial Adipose Tissue Thickness,HbA1c6 month after the treatment	—

Secondary

Measure	Time frame
body weight, voluem of visceral fat, subcutaneous fat, skeletal muscle	—

Countries

Japan

Contacts

Public ContactShusuke Yagi

Institute of Biomedical Sciences, Tokushima University Graduate School Department of Cardiovascular Medicine

syagi@tokushima-u.ac.jp088-633-7851

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026